Posted on Dec 18th, 2009 by Rik J. Deitsch

Dear Fellow Shareholders of Nutra Pharma:

As 2009 comes to a close, I wanted to write this letter to express my gratitude for your continued support and to take a moment to reflect on our progress over the past year.

2009 was a pivotal year for Nutra Pharma. While other companies around the world suffered from the global economic recession, we managed to not only continue operating and financing our clinical studies, but to achieve several important milestones. Our accomplishments this year included launching our first drug, completing and publishing the positive results of several of our clinical studies, upgrading our facilities to meet domestic and international manufacturing standards, filing important patent applications to improve protection of our intellectual property and generating the first significant revenues in the history of our firm.

By far, our greatest accomplishment this year was the launch of our over-the-counter pain reliever, Cobroxin. Developed by our drug discovery subsidiary, ReceptoPharm, Cobroxin has quickly proven itself as a safe and effective treatment for moderate to severe chronic pain. Since its launch in mid-October, Cobroxin has received rave reviews and is continuing to gain traction in the pain market.

In addition to our launch of Cobroxin, our other noteworthy accomplishments in 2009 included:

• filing a patent application for the treatment of arthritis using our lead drug candidate, RPI-78;
• publishing positive results from our arthritis study in the peer reviewed journal, Acta Pharmacologica Sinica;
• achieving ISO Class 5 clean room certification for our laboratory facility, allowing ReceptoPharm to complete Phase I and II sterile drug fills for United States and European clinical trials;
• completing a clinical study showing that our lead drug candidate, RPI-78, is more effective than morphine for the treatment of moderate to severe pain;
• filing a patent application for the oral delivery of cobra venom for the treatment of pain;
• and initiating several international drug registrations in Europe, South America and Canada for our over-the-counter and prescription formulations of Nyloxin for the treatment of chronic pain.

As we move into 2010, we plan to continue building awareness and market share with Cobroxin here in the United States. On a recent webinar, I mentioned several retailers that are planning to carry Cobroxin beginning in the first quarter, including Winn-Dixie, Duane Reade, Hannaford, Meijer, Sweetbay, Big Y, and Stop & Shop among several other national and regional chains. This will be an extremely exciting time as Cobroxin becomes widely available to millions of people in the United States who are suffering from chronic pain.

Not only has Cobroxin allowed us to achieve our humanitarian objectives, but it has allowed us to achieve our business objectives by transitioning us from a research and development stage biotechnology firm into a revenue generating company. This critical step in our growth provides our company with added stability, which is considered a competitive advantage among small and midsize biotechnology companies.

Internationally, we plan to extend the reach of our Nyloxin branded pain relievers, Nyloxin Rx and Nyloxin OTC. We recently completed drug registration in the United States with the Food and Drug Administration for our prescription and over-the-counter formulations of Nyloxin and have begun drug registrations in Canada, Colombia, Brazil, and Europe. We are already planning to initiate several additional registrations throughout Asia and other countries in 2010 as we build our network of international licensees.

As we become cash-flow positive in 2010, many of our shareholders have asked us how we plan to utilize our capital. Currently, we are reinvesting this capital into additional production runs of Cobroxin and Nyloxin. Going forward, we plan to expand our research and development budget to begin several Phase II clinical studies of our leading drug candidates for the treatment of neurological and autoimmune diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Rheumatoid Arthritis (RA). Several of these indications currently lack safe and effective treatments, leaving the opportunity for biotechnology firms like Nutra Pharma to introduce novel therapies.

In closing, I would be remiss if I did not mention our stock performance over the past year. Since the beginning of January, our stock has risen approximately 2,000%. Going forward into 2010, we plan to continue to support our loyal stockholders through increased investor outreach, improved corporate transparency, and more efficient and effective communication with our current and prospective shareholders. As part of this strategy, we welcome any suggestions from our shareholders through our investor relations mailbox, [email protected]. Additionally, I invite you to click here to subscribe to our E-Alerts, which will keep you informed of timely news and announcements from our company.

From all of us at Nutra Pharma, we would like to wish you and your loved ones a happy, healthy and prosperous New Year.

Sincerely yours,
Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation